Nelonemdaz (C007B-378452)

Nelonemdaz (Salfaprodil free base) is an NR2B-selective and uncompetitive antagonist of N-methyl-D-aspartate (NMDA) . Nelonemdaz is also a free radical scavenger. Nelonemdaz has excellent neuroprotection against NMDA- and free radical-induced cell deathIn VitroNelonemdaz (10-300 μM) shows apparent neuroprotection against 300 μM N-methyl-d-aspartate (NMDA) at doses as low as 30 μM. Nelonemdazl (10-500 μM) inhibits the electrophysiologic response of cultured cortical neurons to 300 μM NMDA in a concentration-dependent manner. Nelonemdaz (0.1-1 μM) produces a marked reduction of Fe 2+ -induced neurotoxicity, even at doses of 0.1 to 0.3 μM. Nelonemdaz (0.1-1 μM) blocks the degeneration of neurons and glia in cortical cell cultures. Nelonemdaz (0-350 μM) effectively scavenges superoxide radicals (IC 50 =63.07±1.44 μM), nitric oxide (IC 50 =155.8±4.88 μM), and hydroxyl radicals (IC 50 =58.45±1.74 μM). Nelonemdaz (0.78-12.5 μM) decreases the amount of antimycin A-induced ROS/RNS formation in a dose-dependent manner, with an IC 50 of 2.21±0.11 μM. Nelonemdaz (0.19-12.5 μM) inhibits malondialdehyde (MDA) formation with an IC 50 of 2.72±0.26 μM. Nelonemdaz (0-125 μM) effectively reduces iron-ascorbate-induced lipid peroxidation (IC 50 =24.56±0.07 μM). MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoNelonemdaz (0.5-20 mg/kg; i.v.) reduces cerebral infarct evolving 24 h after 60-mins occlusion of the middle cerebral artery occlusion (MCAO) substantially and dose dependently . Nelonemdaz (5 mg/kg; i.v.) protects white matter such as axons and myelin as well as gray matter from ischemic brain injury . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Sprague-Dawley rats (260 to 300 g) (clip occlusion model) Dosage: 0.5-20 mg/kg Administration: I.v. administration 5 mins after reperfusion Result: Produced a large neuroprotective effect, with a maximal reduction in infarct volume of 66% at doses of 2.5 to 5 mg/kg. Not observed neuronal damage in the most vulnerable cortical area after administration of 5 mg/kg. Animal Model: Male Sprague-Dawley rats (260 to 300 g) (intraluminal thread occlusion model) Dosage: 5 mg/kg Administration: I.v. administration 30 mins after reperfusion Result: Did not change physiologic variables such as arterial pH, PCO 2 , PO 2 , and hematocrit. Reduced infarct volume evolving in the cortex and the striatum substantially. Reduced white matter damage in the striatum and external capsule markedly.Form:SolidIC50& Target:NMDA receptor. Specification: 0.99 Molecular Formula: C15H8F7NO3 Molecular Weight: 383.22 PubChem CID: 9951955 Isomeric SMILES: C1=CC(=C(C=C1NCC2=C(C(=C(C(=C2F)F)C(F)(F)F)F)F)C(=O)O)O

UPC:

51143015

Condition:

New

Weight:

1.06 Ounces

HazmatClass:

No

WeightUOM:

LB

MPN:

N647320-10mg

CAS:

640290-67-1

Product Size:

10mg